Treatment of type 2 diabetes mellitus with GLP-1 receptor agonists and influenceon renal function
General Medicine, 2025, 27(2), 26-30.
N. Kostadinov1, Tsv. Totomirova2
1 University Prof. Dr. Asen Zlatarov – Burgas
2 Clinic of Endocrinology and Metabolic Diseases, MMA ‒ Sofia
Abstract. Type 2 diabetes is a global problem with increasing incidence. Globally, more than one in 10 adults are now living with diabetes. It is the leading cause of chronic kidney disease (CKD) worldwide and its incidence continues to rise. CKD is associated with progressive loss of kidney function. Early stages of CKD may be reversible. Therapeutic control of diabetes is more difficult in patients with renal impairment, requiring a therapeutic approach with increased caution. There are advances in available glucose-lowering agents for the treatment of type 2 diabetes that not only modify the disease itself, but also have important benefits in terms of associated cardiovascular risk factors. The aim of the present study was to investigate the degree of influence on renal function by using GLP-1 receptor agonists in the treatment of type 2 diabetes mellitus.
Key words: type 2 diabetes mellitus, chronic kidney disease, GLP-1 receptor agonists